The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC

  • Authors:
    • Jie Han
    • Yan Xu
    • Yumei Zhou
    • Aiju Yang
    • Jianfeng Cui
    • Pengxiang Chen
    • Hongyu Zhao
    • Xingqin Zhou
    • Chaoyan Shen
    • Jinming Yu
    • Heng Lu
  • View Affiliations

  • Published online on: April 15, 2020     https://doi.org/10.3892/ol.2020.11535
  • Pages: 391-400
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the total progression-free survival (PFS) time of the 1st-line chemotherapy (CHT)/2nd‑line tyrosine kinase inhibitor (TKI) and 1st‑line TKI/2nd‑line CHT therapeutic regimens. Data from patients with non‑small‑cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutations, who had received both TKI and platinum CHT were retrieved from the Shandong Cancer Hospital (Jinan, China) database. A total of 89 patients were included, 50 of whom were treated with the 1st‑line CHT/2nd‑line TKI regimen and the remaining 39 patients underwent a 1st‑line TKI/2nd‑line CHT regimen. The differences in total PFS time between the two regimens were analyzed. The median total PFS time was 14.28 months with the 1st‑line CHT/2nd‑line TKI regimen and 17.77 months with the 1st‑line TKI/2nd‑line CHT regimen (adjusted hazard ratio, 0.96; 95% confidence interval (CI), 0.56‑1.66; P=0.886). A significant difference in PFS time was revealed between the two strategies when comparing only the 1st‑line or 2nd‑line treatments (all P<0.001). The objective response rate (RR) was 52.0% for those treated with 1st‑line CHT/2nd‑line TKI and 38.5% for the reverse regimen. After adjusting for associated factors, the odds ratio for the RR was 2.77 (95% CI: 0.77‑9.90; P=0.117). The current results revealed that there was no significant difference between the total PFS time of patients with NSCLC undergoing the 1st‑line CHT/2nd‑line TKI regimen compared with patients with NSCLC undergoing the 1st‑line TKI/2nd‑line CHT regimen.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Han, J., Xu, Y., Zhou, Y., Yang, A., Cui, J., Chen, P. ... Lu, H. (2020). The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC. Oncology Letters, 20, 391-400. https://doi.org/10.3892/ol.2020.11535
MLA
Han, J., Xu, Y., Zhou, Y., Yang, A., Cui, J., Chen, P., Zhao, H., Zhou, X., Shen, C., Yu, J., Lu, H."The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC". Oncology Letters 20.1 (2020): 391-400.
Chicago
Han, J., Xu, Y., Zhou, Y., Yang, A., Cui, J., Chen, P., Zhao, H., Zhou, X., Shen, C., Yu, J., Lu, H."The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC". Oncology Letters 20, no. 1 (2020): 391-400. https://doi.org/10.3892/ol.2020.11535